Gline Matthew 4

What Happened
Matthew Gline, CEO and Director of Roivant Sciences Ltd. (ROIV), sold 289,774 common shares on April 16, 2026. The filing reports a weighted average sale price of $29.16 per share, for total proceeds of approximately $8,449,810. The filing indicates the sale occurred in multiple transactions.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-20 (timely; within the two-business‑day reporting window).
• Transaction type: Sale (open‑market / multiple transactions).
• Shares sold: 289,774; weighted average price: $29.16; total proceeds: ~$8,449,810.
• Price range: $28.98 to $29.36 (footnote F1 notes the reported price is a weighted average and the filer can provide a breakdown by trade price on request).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5‑1 plan, tax‑withholding, option exercise, or gift was reported in the provided details.

Context
This was a sale by the company’s CEO. Sales by insiders can be routine (e.g., diversification or liquidity needs) and do not, by themselves, prove a change in the insider’s view of the company. Purchases are generally viewed as stronger signals of insider conviction than sales.